A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Status:
Completed
Trial end date:
1992-04-01
Target enrollment:
Participant gender:
Summary
To study the safety and maximum tolerated dose (MTD) of combined chemotherapy when it is
administered to patients with advanced Kaposi's sarcoma together with one of two different
doses of zidovudine (AZT).
The combination of AZT and chemotherapy may be effective in treating the tumor as well as
preventing the life-threatening infections when used for patients with AIDS and Kaposi's
sarcoma. The MTD of combined chemotherapy is being determined so that the information will be
available for future studies, when the relative effectiveness of the two doses of AZT has
been learned.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)